Previous 10 | Next 10 |
home / stock / onppf / onppf news
Many wonder about an upcoming bear market. For me, this is a simple answer - the bear is already here. At least in Sweden and Scandinavia and for some companies. For months now since early August, the indexes here have been punished, and we're down more than 10%, correction. However, ...
Oncopeptides presents phase 3 OCEAN study results at the IMW meeting PR Newswire STOCKHOLM , Sept. 11, 2021 /PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat he...
Oncopeptides AB (ONPPF) announces updated results and safety measures based on Phase 3 OCEAN study evaluating the efficacy and safety of melflufen (INN melphalan flufenamide) plus dexamethasone vs. pomalidomide plus dexamethasone in patients with relapsed refractory multiple myeloma who have ...
Bulletin from the Annual General Meeting in Oncopeptides AB (publ) PR Newswire STOCKHOLM , May 26, 2021 /PRNewswire/ -- The Annual General Meeting in Oncopeptides AB (publ) (ONCO) was held on Wednesday, 26 May 2021 . At the Annual General Meeting, the followi...
Oncopeptides AB (ONPPF) posts topline results from the head-to-head phase 3 OCEAN study evaluating the efficacy and safety of melphalan flufenamide versus pomalidomide in patients with relapsed refractory multiple myeloma ((RRMM)).The Overall Response Rate ((ORR)) for melphalan fluf...
Oncopeptides AB (ONPPF): Q1 GAAP EPS of -SEK3.45.Net sales of SEK19.4M.Cash and cash equivalents of SEK872.5MPress Release For further details see: Oncopeptides AB reports Q1 results
Oncopeptides completes patient enrollment in phase 2 PORT study PR Newswire STOCKHOLM , May 5, 2021 /PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hemat...
Oncopeptides publishes the 2020 Annual Report PR Newswire STOCKHOLM , April 26, 2021 /PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseas...
Oncopeptides submits application for conditional marketing authorization of melflufen in the EU PR Newswire STOCKHOLM , April 16, 2021 /PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapie...
Number of shares and votes in Oncopeptides PR Newswire STOCKHOLM , March 31, 2021 /PRNewswire/ -- Oncopeptides AB (Nasdaq Stockholm, ONCO) today announces that the number of shares and votes in Oncopeptides has changed due to the exercise of warrants under the ...
News, Short Squeeze, Breakout and More Instantly...
Oncopeptides Company Name:
ONPPF Stock Symbol:
OTCMKTS Market:
FDA announces an Oncologic Drugs Advisory Committee meeting to discuss benefit/risk profile of Oncopeptides' Pepaxto PR Newswire STOCKHOLM , July 20, 2022 /PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on resear...
Oncopeptides rescinds voluntary withdrawal of Pepaxto in the US - no intent to market in the US at this time PR Newswire STOCKHOLM , Jan. 21, 2022 /PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and deve...
Oncopeptides presents phase 3 OCEAN study results at the IMW meeting PR Newswire STOCKHOLM , Sept. 11, 2021 /PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat he...